Image Place holder

Jing-Yi Chern, MD, ScM

Specialty: Gynecologic Oncology
Program: Gynecologic Oncology

Call 1-888-MOFFITT

or call 1-888-MOFFITT


Dr. Chern is a Gynecologic Oncologist.  After earning her Master’s Degree in Biochemistry and Molecular Biology at the Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Dr. Chern completed her Medical Degree at the College of Medicine, University of South Florida. She subsequently completed her Residency in Obstetrics and Gynecology at the College of Medicine, University of South Florida, where she served as Administrative Chief Resident and Scientific Review Committee Member. During her residency training, Dr. Chern received a Galloway Fellowship, awarding her the opportunity to perform a rotation at Memorial Sloan-Kettering Cancer Center in New York. Dr. Chern completed her Gynecologic Oncology Fellowship at New York University School of Medicine, where she earned a Certificate in Translational Research Methodologies under the Clinical and Translational Science Institute at New York University.Dr. Chern’s research interest includes evaluating quality and safety measures to improve surgical outcomes in patients with malignancies. Her research  focuses on the utility of multigene panel testing with next-generation sequencing in women with endometrial cancer, as well as the role of genetic counseling and testing in capturing women at high risk for endometrial and ovarian cancers. Dr. Chern's research also focuses on the impact of genetics in the development of these cancers in women. Dr. Chern has worked as part of a multi-disciplinary team to develop new protocols and safety measures with the goal of improving post-operative outcomes and patient satisfaction. In addition, her research is focused on understanding genetic mutations and its relationship to gynecologic malignancy. Her work has been presented at national meetings.    

Education & Training

Board Certification:


    • New York University School of Medicine - Gynecologic Oncology
    • Memorial Sloan Kettering - Galloway Fellowship


    • University of South Florida - Obstetrics & Gynecology

    Medical School:

    • University of South Florida - MD
    Participating Trials

    If you believe you are eligible for one of these trials or studies, please call
    1-888-MOFFITT (1-888-663-3488).


    • Chern JY, Boyd LR, Blank SV. Uterine Sarcomas: The Latest Approaches for These Rare but Potentially Deadly Tumors. Oncology (Williston Park). 2017 Mar;31(3):229-236. Pubmedid: 28299760.
    • Frey MK, Ellis AE, Koontz LM, Shyne S, Klingenberg B, Fields JC, Chern JY, Blank SV. Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum. Gynecol Oncol. 2017 Aug;146(2):386-391. Pubmedid: 28602549.
    • Lee J, Aphinyanaphongs Y, Curtin JP, Chern JY, Frey MK, Boyd LR. The safety of same-day discharge after laparoscopic hysterectomy for endometrial cancer. Gynecol Oncol. 2016 Sep;142(3):508-513. Pubmedid: 27288543.
    • Frey MK, Moss HA, Musa F, Rolnitzky L, David-West G, Chern JY, Boyd LR, Curtin JP. Preoperative experience for public hospital patients with gynecologic cancer: Do structural barriers widen the gap?. Cancer. 2016 Mar;122(6):859-867. Pubmedid: 26938270.
    • Chern JY, Curtin JP. Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer. CURR TREAT OPTION ON. 2016 Jan;17(1):1. Pubmedid: 26714493.
    • Frey MK, Kim SH, Bassett RY, Martineau J, Dalton E, Chern JY, Blank SV. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening. Gynecol Oncol. 2015 Nov;139(2):211-215. Pubmedid: 26296696.
    • McLoughlin J, Melis M, Siegel E, Dean E, Weber J, Chern J, Elliott M, Kelley S, Karl R. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer?. J Am Coll Surg. 2008 May;206(5):879-886. Pubmedid: 18471715.
    • Hohenstein KA, Pyle AD, Chern JY, Lock LF, Donovan PJ. Nucleofection mediates high-efficiency stable gene knockdown and transgene expression in human embryonic stem cells. Stem Cells. 2008 Jun;26(6):1436-1443. Pubmedid: 18323409. Pmcid: PMC3882114.
    • Charron M, Chern JY, Wright WW. The cathepsin L first intron stimulates gene expression in rat sertoli cells. Biol Reprod. 2007 May;76(5):813-824. Pubmedid: 17229931.